Genmab AS
(NASDAQ: GMAB)
|
5:00 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $25.15 | Change: +0.25 | %Change: +1.00% | Volume: 236,520 |
Open: | $ 25.10 | Volume: | 236,520 | |
---|---|---|---|---|
High: | $ 25.27 | Yield(%) | 0.00 | |
Low: | $ 25.08 | P/E Ratio (ttm): | 20.47 | |
Dividend ($): | n/a | Market Cap ($): | 16.22B | |
EPS ($) | 1.22 | Shares Out: | 651.55M |
% Price Change (last 4 weeks): | -12.63 |
---|---|
% Price Change (last 13 weeks): | -16.89 |
% Price Change (last 26 weeks): | -22.45 |
% Price Change (last 52 weeks): | -34.75 |
% Price Change (year to date): | -21.80 |
Return on Equity (%): | 14.65 |
---|---|
Return on Assets (%): | 13.19 |
Return on Invested Capital (%): | 19.27 |
Gross Profit Margin (%): | 96.64 |
---|---|
Net Profit Margin (%): | 26.42 |
Operating Profit Margin (%): | 32.30 |
|
|
50-day Moving Average: | $27.88 |
---|---|
200-day Moving Average: | $30.04 |
Avg. Daily Vol. (last 50 days): | 532,124 |
Avg. Daily Vol. (last 200 days): | 654,367 |
52-wk high: | $42.72 |
52-wk low: | $24.53 |
Bid: | $25.20 |
Ask: | $26.00 |
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
|
Genmab AS
Carl Jacobsens Vej 30 Valby Copenhagen CD 2500 Phone: 45.70.20.27.28 Fax: n/a http://www.genmab.com |
Earnings (1year) ($): | 1.22 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | 20.47 |
Book Value ($): | 7.17 |
Cash Flow ($): | 1.04 |
Price/Earnings (x): | 20.47 |
---|---|
Price/Sales (x): | 8.78 |
Price/Book (x): | 4.44 |
Price/Cash Flow (x): | 19.60 |
Quick Ratio (x): | 13.32 |
---|---|
Current Ratio (x): | 13.34 |
LT Debt/Equity (x): | 2.15 |
Total Debt/Equity (x): | 2.44 |